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It is well known that lowering of elevated plasma lowdensity lipoprotein (LDL) cholesterol is most important to decrease the risk of the development of coronary heart disease (CHD) and the risk of cardiovascular events in general. The treatment of elevated LDLcholesterol must always start with lifestyle modifications. However, most patients will besides lifestyle modification need to take a medicine in order to achieve their LDL-cholesterol target values according to their cardiovascular risk. 1 The medicines that are still the gold standard for lowering elevated LDLcholesterol in both primary and secondary prevention are statins. 2 However, despite intensive statin therapy with the highest tolerable doses, even when ezetimibe is added to the statin treatment, a significant number of high and very high risk patients are unable to achieve the recommended target LDL-cholesterol levels.
Proprotein-convertase-subtilisin/kexin type 9 (PCSK9) enhances the endosomal and lysosomal degradation of hepatic low-density lipoprotein receptor (LDLR), resulting in increased serum LDL-cholesterol levels. Therefore, PCSK9 is considered to be a key regulator of plasma LDL-cholesterol levels. Loss-offunction mutations of PCSK9 are associated with significantly decreased serum LDL-cholesterol levels, while gain-of-function mutations in PCSK9 result in one form of familial hypercholesterolemia (FH). FH is a genetic disease characterised by extremely elevated levels of LDL-cholesterol (the other forms of FH are caused by changes of LDLR, apolipoprotein B (apoB) or STAP1 coding signal transducing adaptor family member 1).
Antibodies to PCSK9 have been developed to decrease LDL-cholesterol further. They are used particularly in very high and high risk patients who are unable to achieve the recommended target LDL-cholesterol levels despite treatment with the highest tolerable doses of a statin plus ezetimibe. 4 This is especially often needed in FH patients. 3 Two major studies with PCSK9 antagonists -FOURIER with evolocumab and ODYSSEY OUTCOMES with alirocumab -have recently shown that the adding of these drugs to a statin and ezetimibe can significantly reduce CHD death, non-fatal myocardial infarction, unstable angina requiring hospitalisation and ischaemic stroke.
5
PCSK9 levels in plasma have been shown to correlate positively with the LDL-cholesterol levels but the data on this are not unequivocal. There are also data that circulating PCSK9 levels positively correlate with the LDL-apolipoprotein (apo) B100 fractional catabolic rate. This suggests that PCSK9 might be a marker of LDL particle catabolism. However, the correlation between PCSK9 and the LDL-cholesterol level has been shown to be less significant than expected for several reasons. 6 The details of PCSK9 metabolism and the control of PCSK expression have been described in the article by Macchi et al. published in this issue of the journal. 7 It is well known that statins activate LDLRs as well as PCSK9 gene expression thus increasing circulating PCSK9 levels. This most probably diminishes the effect of statins on the reduction of plasma LDL-cholesterol levels. Nevertheless, as there are still many open questions concerning the clinical validity of measurements of circulating PSCK9 levels for cardiovascular risk prediction, there are even more doubts about the putative usefulness of PCSK9 as a biomarker of lipid metabolism in clinical practice in patients treated with lipidlowering drugs. Namely, it has been suggested that statin treatment can completely abolish the correlation between PCSK9 and the plasma LDL-cholesterol level. 8 If this is true, measuring plasma PCSK9 levels in patients treated with statins would not be particularly useful in routine clinical practice. Concerning the predictive value of PCSK9 in individuals who are not treated with statins, a meta-analysis of nine studies (12,081 participants, mean follow-up 6.62 years) suggested that circulating PCSK9 levels were modestly but significantly associated with an increased risk of total cardiovascular events. 9 This was not so clear in patients from the DIABHYCAR (n ¼ 3137) and the SURDIAGENE (n ¼ 1468) studies -two cohorts of patients with type 2 diabetes mellitus. In this most recent study the association seemed to depend on the level of cardiovascular risk and the background lipidlowering treatment. 10 It has to be mentioned that there are also several new approaches to inhibit PCSK9. They include blocking the binding of PCSK9 to LDLR using, besides antibodies, adnectins and mimetic peptides; inhibiting PCSK9 expression using CRISPR/Cas9 genome-editing technology, antisense oligonucleotides, small interfering RNA -e.g. inclisiran, as well as small molecules (berberine, oleanoic acid); and interfering with PCSK9 secretion from the endoplasmic reticulum using agents such as sortilin and Sec24a. There are very few data on whether these substances have any impact on circulating PCSK9 levels.
Concerning other lipid-lowering drugs, ezetimibe seems to be unable to increase PCSK9 concentrations most probably because of its weak LDL-cholesterollowering effect. The effect of fibrates on circulating PCSK9 seems to differ depending on the type of fibrate.
As a conclusion it seems that additional studies are needed to answer without any doubt whether there is clinical validity of circulating PCSK9 level determination not only as a possible predictor or qualifier for cardiovascular risk estimation but even more as a possible diagnostic tool for explaining resistance to PCSK9 inhibitors. In addition, randomised studies with higher doses and other types of statins are also needed explicitly to address the question of the influence of these drugs on circulating PCSK9 levels.
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